Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals
Posted inAllergy & Immunology Neurology news

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals

A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–moderate AD.
Aducanumab Removes Superficial Cortical Amyloid but Associates with Local Vascular Injury and ARIA: Clinicopathological Evidence from a Retrospective Case–Control Study
Posted inNeurology news

Aducanumab Removes Superficial Cortical Amyloid but Associates with Local Vascular Injury and ARIA: Clinicopathological Evidence from a Retrospective Case–Control Study

Autopsy of aducanumab-treated Alzheimer’s cases shows preferential clearance of superficial layer I amyloid, PET Centiloid reductions, and ARIA-associated microvascular pathology, implicating perivascular amyloid removal and vessel injury as mechanisms that inform monitoring and therapy design.
Two-Year 40 Hz Audiovisual Stimulation in Mild Alzheimer’s: Safety, EEG Entrainment, and Early Biomarker Signals
Posted inNeurology news

Two-Year 40 Hz Audiovisual Stimulation in Mild Alzheimer’s: Safety, EEG Entrainment, and Early Biomarker Signals

An open-label two-year extension in five patients with mild Alzheimer's disease found daily 1‑hour 40 Hz audiovisual stimulation to be safe, produced sustained EEG gamma entrainment in late‑onset cases, and was associated with smaller cognitive decline and reductions in plasma pTau217 in two participants, warranting controlled trials.